Contact SCGE




Clinical Trial Report

Gene Therapy Trial Report

Summary

Safety and Efficacy of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (VENUS)

NCTID NCT06196840 (View at clinicaltrials.gov)
Description
Indication Neovascular (Wet) Age-Related Macular Degeneration
Compound Name LX102
Sponsor Innostellar Biotherapeutics Co.,Ltd
Funder Type Industry
Status
Recruiting
Enrollment Count 50

Therapy Information

Target Gene/Variant VEGF-trap
Therapy Type Gene transfer
Therapy Route In-vivo
Mechanism of Action Genetic delivery of therapeutic protein
Route of Administration Subretinal
Drug Product Type Viral vector
Target Tissue/Cell
Delivery System Viral transduction
Vector Type AAV2
Editor Type
Dose 1 2 x 10^10 vg
Dose 2 Undisclosed dose 2
Dose 3
Dose 4
Dose 5

Study Record Dates

Current Stage Phase2
Submit Date 2023-12-25
Completion Date 2029-05
Last Update 2024-01-09

Participation Criteria

Eligible Age 50 Years - 89 Years
Standard Ages Adult, Older adult
Eligible Sex ALL

Locations

No.of Trial Sites 3
Locations China

Regulatory Information

Has US IND False
Recent Updates

Resources/Links

Clinical Publications